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Methods: The Clinical and Health Outcomes Initiative in Comparative
Effectiveness for Bipolar Disorder study (Bipolar CHOICE) enrolled 482 participants with bipolar I or bipolar II disorder in a six-month, randomized comparative effectiveness trial. Baseline assessments included current and lifetime DSM-IV-TR diagnoses, demographic information, psychiatric and medical history, severity of psychiatric symptoms, level of functioning, and a fasting blood draw. Medical comorbidities were categorized into two groups: cardiometabolic (e.g., diabetes, hyperlipidemia, and metabolic syndrome) and noncardiovascular (e.g., seizures, asthma, and cancer). Additionally, we looked at comorbid substance use (e.g., smoking and drug dependence).
Results: We found that 96.3% of participants had at least one other medical comorbidity. Older age predicted a greater likelihood of having a cardiometabolic condition. Early age of onset of bipolar symptoms was associated with a lower chance of having a cardiometabolic condition, but a greater chance of having other types of medical comorbidity. Additional predictors of other medical comorbidities in bipolar disorder included more time spent depressed, less time spent manic/hypomanic, and longer duration of illness. Medications associated with weight gain were associated with low high-density lipoprotein and abnormal triglycerides.
Conclusions: There appears to be a substantial medical burden associated with bipolar disorder, highlighting the need for collaborative care among psychiatric and general medical providers to address both psychiatric and other medical needs concomitantly in this group of patients. Individuals with bipolar disorder have high rates of medical comorbidities in addition to chronic, debilitating mood symptoms and impairments in functioning (1) (2) (3) (4) (5) . Previous studies have found that over 50% of individuals with bipolar disorder have at least one medical comorbidity (6) (7) (8) ; patients are at increased risk for cardiovascular disease (9-13), respiratory disorders (14, 15) , thyroid disease (16) , hepatitis C (17), type-2 diabetes (18), and obesity (19, 20) , as compared to rates in the general population. This medical burden in bipolar disorder is associated with a higher rate of morbidity and mortality (21) (22) (23) and a 30% shorter life expectancy (24) . It is also associated with increased costs of medical care and loss of productivity (25) , worse course of bipolar illness (i.e., more episodes, longer duration of episode, and poor functioning) (6, (26) (27) (28) (29) , and higher rates of treatment with psychotropic medications (6) . Moreover, medications commonly prescribed to treat bipolar disorder can exacerbate risks of metabolic disturbances (30, 31) and cardiovascular disease (32) (33) (34) .
Louisa
Given the negative impact of this substantial medical burden in bipolar disorder, it is vital to understand what features of bipolar disorder contribute to this increased risk of comorbidity. Extant research in bipolar disorder has limited generalizability, as it has tended to be focused only on a few possible medical conditions (17, 35) or on specific subgroups, such as elderly people (36, 37) , or homogenous samples (15, 27) . Thus, the aim of the present study was to assess the rates of different comorbidities in a large, heterogeneous sample of individuals with bipolar disorder, and to assess demographic and clinical predictors of such comorbidity. We expected that rates of comorbid cardiometabolic conditions (e.g., type 2 diabetes) and other medical comorbidities (e.g., asthma and cancer) would not differ by bipolar subtype, but that worse course of illness (i.e., longer duration, more frequent mood episodes, and poor functioning) and earlier age of onset would be associated with an increased likelihood of having medical comorbidities. We also expected that medications known to induce weight gain would be associated with greater metabolic disturbances.
Materials and methods

Procedures
The Clinical and Health Outcomes Initiative in Comparative Effectiveness for Bipolar Disorder study (Bipolar CHOICE) (38) was a six-month, multi-site, randomized comparative effectiveness trial comparing a classic mood stabilizer (lithium) to a common antipsychotic used to treat bipolar disorder (quetiapine). Study physicians were able to prescribe additional medications as needed (although antipsychotics were excluded in patients randomized to lithium, and other antipsychotics and lithium were excluded in patients randomized to quetiapine) as long as medications were consistent with the guidelines used to treat bipolar disorder (39) and personalized to the needs of the patient (40) . The rationale, design, and methods of Bipolar CHOICE are reported elsewhere (38) . The present study examined data from the baseline visit (see Fig. 1 ).
Participants
The Institutional Review Boards of the 11 sites approved the study protocol. Bipolar CHOICE enrolled 482 individuals between the ages of 18 and 68 years. Limited inclusion and exclusion criteria were designed to maximize heterogeneity of the sample and hence generalizability of results (38) , but participants were required to have a DSM-IV-TR bipolar I or bipolar II diagnosis and be at least mildly symptomatic [Clinical Global Impression Scale for Bipolar Disorder (CGI-BP) ≥ 3] at study entry.
Psychiatric and substance use diagnoses were determined using the extended Mini-International Neuropsychiatric Interview, an electronic version of a validated structured diagnostic interview (41) . The CGI-BP assessed bipolar illness severity on three separate subscales for mania, depression, and overall bipolar illness, ranging from 1 to 7 (normal to very severely ill) (42) . Psychiatric symptom severity and overall functioning and life satisfaction were measured with the Bipolar Inventory of Symptoms Scale (BISS) (43, 44) and LIFE-Range of Impaired Functioning Tool (LIFE-RIFT) (45), respectively. Clinical interviews obtained demographic information, psychiatric/medical history (e.g., asthma, myocardial infarction, and hepatitis) and current medications. A fasting blood draw was also conducted to assess cardiometabolic variables such as levels of triglycerides and cholesterol.
Statistical analyses
Medical comorbidities were divided into two groups to understand specific trends in the conditions associated with bipolar disorder: (Group 1) cardiometabolic disturbances (coronary artery disease, myocardial infarction, diabetes, hyperglycemia, hyperlipidemia, hypercholesterolemia, triglyceridemia, and metabolic syndrome); (Group 2) non-cardiovascular conditions (kidney disease, seizures, thyroid disease, asthma, migraines, cancer, hepatitis, and head trauma). Comorbid substance use (smoking, alcohol and drug abuse/ dependence) was also included in the analyses. The rationale for these groupings was that we expected cardiometabolic disorders and substance use to be particularly associated with the course of bipolar disorder (6) .
Predictors of medical comorbidity were tested using chi-square tests for categorical variables and t-tests for continuous variables. If an overall chisquare was significant, we used logistic regression to determine specific contrasts of interest. The primary analysis assessed the association of medical disorders with demographic characteristics and clinical features of bipolar disorder. Analyses involving number of lifetime depressive/manic episodes and total number of years depressed/manic were adjusted for age. All predictors were then considered for entry into multivariate models using stepwise logistic regression to evaluate which variables uniquely predicted medical comorbidity. Finally, we assessed whether reported use of medications known to induce weight gain (lithium, valproate, clomipramine, imipramine, amitriptyline, mirtazapine, clozapine, olanzapine, quetiapine, or risperidone) correlated with cardiometabolic disturbances at baseline.
Results
Demographic and clinical features are reported in Table 1 . In this sample, we found that 96.3% of participants met criteria for at least one medical Includes patients with any one of the following current diagnoses (based on the MINI): panic disorder, agoraphobia, social phobia, and generalized anxiety disorder. comorbidity, 71.2% for at least one cardiometabolic disturbance (Group 1), 56.2% for at least one other non-cardiometabolic, medical comorbidity (Group 2), and 80.5% for substance use (Group 3). Notably, more than 70% of participants reported being current or past smokers. Substance use was more prevalent in bipolar I than bipolar II disorder (Table 2) .
Older participants were more likely to have a Group 1 condition. A later age of onset, more depressive symptoms, and fewer manic symptoms at baseline were associated with a higher likelihood of having a Group 1 disorder. Spending more time in the past year manic/hypomanic and current manic/hypomanic symptoms (BISS) corresponded to a decreased likelihood of having a Group 1 disorder, such that a 20% increase in time spent manic/hypomanic decreased the odds of a Group 1 disorder by 23% (Table 3) . For each 20% increase in time depressed in the last year (e.g., from 0-20% to 20-40%), the odds of a Group 1 disorder increased by 18%, though the effect was marginally significant (p = 0.069).
Female gender, greater percentage of time spent depressed, presence of lifetime substance use disorder, younger age of illness onset, and longer duration of illness (even when controlling for participants' age) predicted Group 2 conditions (Tables 3 and 4) . When controlling for age, participants who reported spending a larger percentage of the past year depressed were more likely to have at least one Group 2 condition. Each 20% increase in time depressed elevated the odds of a Group 2 disorder by 23%.
The likelihood of meeting criteria for substance use (Group 3) was significantly associated with race, lower household income, older age, lower education level, comorbid anxiety disorder diagnosis, and worse depression and life functioning (LIFE-RIFT) as well as greater illness severity (CGI-BP overall and depression; percentage of past year spent depressed) (Tables 3 and 4 ). Follow-up tests showed that Asians had 27% lower odds of substance use than non-Asians. Finally, medications associated with weight gain were associated with low high-density lipoprotein (HDL) cholesterol and abnormal (high) triglycerides (Table 5 ).
In our multivariate models (i.e., each variable is adjusted for all other covariates in the model), we found that older age and less severe manic symptoms remained associated with the presence of Group 1 conditions [95% confidence interval (CI): 1.03-1.07, p < 0.001; 95% CI: 0.91-0.97, p < 0.001, respectively]. In Group 2, female gen- Values are reported as %. Criteria were based on either medical history or laboratory values. Hyperglycemia was defined as being present if fasting blood glucose ≥100 mg/dL; high total cholesterol if total cholesterol ≥240 mg/dL; low high-density lipoprotein cholesterol (HDL-C) if HDL-C <50 mg/dL (female) or <40 mg/dL (male); high low-density lipoprotein cholesterol (LDL-C) if LDL-C ≥130 mg/dL; high triglycerides if triglycerides ≥150 mg/dL; metabolic syndrome if three or more of the following criteria were met: waist circumference >35 inches (female) or >40 inches (male), triglycerides ≥ 150 mg/dL, HDL-C <50 mg/dL (female) or <40 mg/dL (male) or participant on medications for hypercholesterolemia, systolic blood pressure <130 mm Hg or diastolic blood pressure >85 mm Hg or participant on medications for hypertension, or fasting blood glucose ≥100 mg/dL or participant on medications for diabetes. 
Discussion
This study is consistent with previous data demonstrating high rates of medical comorbidity in bipolar disorder (11, 13, 46) , but extends these data by highlighting specific associations among these conditions with specific demographic and clinical features. For example, a complicated association of age and age of bipolar illness onset with medical comorbidity. Consistent with findings for nonbipolar samples, the likelihood of having a cardiometabolic condition (Group 1) as well as substance use increased with age (47, 48) which remained significant in the multivariate models; however, this finding did not hold for other, non-cardiovascular medical conditions (Group 2). This may suggest that, with age, bipolar patients are susceptible to developing cardiometabolic disease and substance problems, or conditions associated with unhealthy lifestyle choices, but not necessarily other medical conditions. This finding may also be explained by migraines and asthma having early ages of onset as they were the most prevalent Group 2 conditions (49-51).
We found that an earlier age of onset and longer duration of illness, independent of age and other variables, predicted having a Group 2 condition (which remained significant in the multivariate analyses) and later age of onset was associated with a greater likelihood of having a Group 1 condition. Thus, perhaps cardiometabolic conditions that develop with age (as discussed above) could trigger a later onset of bipolar disorder, as these medical conditions are risk factors for depressive symptoms and mood episodes (27, 52, 53) . Alternatively, perhaps Group 1, cardiometabolic conditions and substance use, or those most modifiable, become the focus of treatment instead of psychiatric conditions, such as bipolar disorder, resulting in later detection or age of onset. Similarly, low income was associated with substance use, presenting another potential barrier to diagnosis or treatment. Further research is needed to better understand these data.
More severe manic symptoms were unexpectedly associated with a decreased likelihood of having a cardiometabolic condition, which remained significant in the multivariate models. These data might be explained by depression having a causal link to cardiometabolic health (6, 29) ; more mania in the last year could reduce the time spent depressed, therefore reducing the exposure to the depressed state and the associated cardiometabolic risk. Furthermore, depressed patients may be more likely to gain weight than manic patients (54) . Recent studies have also shown that increased manic symptoms may be correlated with more frequent exercise, which could also account for this finding Criteria were based on either medical history or laboratory values. Hyperglycemia was defined as being present if fasting blood glucose ≥100 mg/dL; high total cholesterol if total cholesterol ≥240 mg/dL; low high-density lipoprotein cholesterol (HDL-C) if HDL-C <50 mg/dL (female) or <40 mg/dL (male); high low-density lipoprotein cholesterol (LDL-C) if LDL-C ≥130 mg/dL; high triglycerides if triglycerides ≥150 mg/dL. a Weight-gain medications = amitriptyline, aripiprazole, clomipramine, clozapine, doxepin, imipramine, lithium, mirtazepine, olanzapine, quetiapine, risperidone, and valproate. (55, 56) . Nearly half of our sample experienced less than 20% of the previous year in an elevated mood state; thus, it is also possible that the sample experiencing elevated mood was not large enough for us to detect an association. Yet, Fiedorowicz and colleagues found that manic symptoms were associated with increased cardiovascular mortality, independent of cardiovascular risk factors present at baseline, age, and gender (57) . Finally, medications prescribed for bipolar disorder, such as mood stabilizers and antipsychotics, were associated with low HDL and high triglyceride levels, as expected given that these medications are typically associated with risk factors for cardiovascular disease (30, 31 ). Yet, other parameters (e.g., hypertension, hyperlipidemia, and diabetes) were not associated with these medications. This may be due to a lack of power given the lower prevalence of these conditions in our sample, although the data did not trend in this direction. Alternatively, providers may be becoming more conservative in prescribing these medications given their known deleterious side effects.
Limitations of the current study include relying on self-report of substance use and Group 2 conditions as well as these data being assessed only at one time-point which does not allow us to draw any causal conclusions. Data were collected through a clinical trial, potentially limiting the generalizability of the findings. There may also be overlap between the groups, as lifetime substance use predicted the presence of a Group 2 condition. Of note, the other medical comorbidity group (Group 2) includes several medical conditions and thus, the heterogeneity of Group 2 is a potential limitation. Finally, the lack of a control group limits our ability to discern if these effects are unique to the bipolar population; however, the findings with mania (negative correlation with cardiometabolic conditions and positive correlation with substance use) do present an important and specific relationship with bipolar disorder.
Despite these potential limitations, these data highlight the substantial medical burden in bipolar disorder, but perhaps more to the point, that medical comorbidities could often reflect the effects of the illness and not the conditions themselves. We hope that, by elucidating the potential interplay between bipolar disorder and its high medical burden, we will improve the treatment of the disease (e.g., highlight the need for greater collaboration between providers, and increase awareness that depression or age of onset is associated with specific medical conditions). This is important as patients with bipolar disorder are frequently unaware of their predisposition for medical comorbidities and most of the illnesses can be prevented (6, 58) . Thus, these data highlight the need to adopt strategies to reduce medical burden in bipolar disorder as well as to integrate medical and psychiatric care for these patients with the aim to improve overall outcomes.
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